title: Qualitative assessment of blood washing with the continuous autologous transfusion system (CATS)
abstract: A number of different blood-processing methods can be used at the end of cardiopulmonary bypass (CPB) to improve the quality of autologous blood. They include centrifugation, hemofiltration and cell-washing. They differ in processing time required, cost of disposables and the quality of the processed autologous blood product. The newly developed continuous auto-transfusion system (CATS: Fresenius AG, Bad Homburg) uses a continuous cell-washing method. In a prospective study, the oxygenator blood of 10 patients was processed at the end of cardiac surgery with CATS and the quality of autologous blood before and after processing was compared. The processing volumes and the time required were recorded. The concentrations and elimination rates of blood parameters and waste products such as activated coagulation and complement products were measured. At the end of CPB a mean volume of 1,010 +/- 174 ml diluted oxygenator blood was processed and concentrated to 310 +/- 88 ml in 11.0 +/- 2.2 mins. Cellular elements such as erythrocytes and leucocytes were mostly retained and their concentration showed a significant increase after processing (250% and 210% respectively; p < 0.01). Thus, the blood processing with CATS resulted in an excellent hemoconcentration (hematocrit 62 +/- 3 vs. 24 +/- 4% before processing) with a consistent reproducibility. On the other hand, the CATS concentrate showed a significant loss of autologous plasma proteins. Likewise, all water soluble elements such as waste products are significantly lower in concentration after processing and, if calculated by quantity, they show a high elimination rate (> 93%). In conclusion, the continuous autologous transfusion system permits an automated, rapid and continuous processing of autologous blood yielding a standardised high quality erythrocyte concentrate.
authors.affiliation: Department of Thoracic and Cardiovascular Surgery, University of Berne, Switzerland.
authors.forename: B H
authors.initials: BH
authors.lastname: Walpoth
authors.forename: N
authors.initials: N
authors.lastname: Eggensperger
authors.forename: B N
authors.initials: BN
authors.lastname: Walpoth-Aslan
authors.forename: P
authors.initials: P
authors.lastname: Neidhart
authors.forename: M
authors.initials: M
authors.lastname: Lanz
authors.forename: R
authors.initials: R
authors.lastname: Zehnder
authors.forename: P J
authors.initials: PJ
authors.lastname: Spaeth
authors.forename: G
authors.initials: G
authors.lastname: Kurt
authors.forename: U
authors.initials: U
authors.lastname: Althaus
mesh_terms: D000368:Aged; D001772:Blood Cell Count; D001774:Blood Chemical Analysis; D001780:Blood Coagulation Tests; D001781:Blood Component Removal; D001798:Blood Proteins / Q000378:metabolism; D001804:Blood Transfusion, Autologous / Q000592:standards*; D002315:Cardiopulmonary Bypass; D005260:Female; D006400:Hematocrit; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011786:Quality Control; D015203:Reproducibility of Results; D016060:Sorption Detoxification / Q000592:standards*; D016896:Treatment Outcome
chemical_list: D001798:Blood Proteins; D006454:Hemoglobins